



UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
WASHINGTON, D.C. 20549

DIVISION OF  
CORPORATION FINANCE

February 10, 2021

Bruce Jacobs  
Chief Financial Officer  
200 Arsenal Yards Blvd.  
Suite 230  
Watertown, Massachusetts

**Re: KYMERA THERAPEUTICS, INC.**  
**Form 10-Q for the quarterly period ended September 30, 2020**  
**Exhibit No. 10.2**  
**Filed November 5, 2020**  
**File No. 001-39460**

Dear Mr. Jacobs:

We have concluded our assessment of your redacted exhibit for compliance with applicable form requirements and will process your supplemental response and related materials in accordance with your request.

Sincerely,

Division of Corporation Finance